FathomX

✨ FathomX founders and National University of Singapore professors Mengling 'Mornin' Feng and Mikael Hartman featured by NUHS: "How deep tech is revolutionising mammogram screening. Powered by artificial intelligence, a novel tool called FxMammo holds promise for better, faster and smarter breast cancer detection." "FxMammo is the flagship product of FathomX, a medtech company spun off from the National University of Singapore (NUS) and the National University Health System (NUHS). A/Prof Mikael Hartman, Head and Senior Consultant, Division of General Surgery (Breast Surgery), Department of Surgery, NUH, developed FxMammo in collaboration with A/Prof Feng Mengling from the NUS Saw Swee Hock School of Public Health (SSHSPH). Together, they co-founded FathomX to commercialise this innovative solution." #AI #medicalimaging #radiology #breastcancer #femalehealth https://lnkd.in/dQRJe9Q3

⭐ FathomX is pleased to announce that our AI-driven breast cancer diagnostic tool, FxMammo, will be offered in Japan through LPIXEL Inc.’s EIRL AI Partner Program. This partnership provides a commercially ready pathway for AI-solution FxMammo to enter the Japanese market via LPIXEL’s well-established platform, currently deployed in over 900 medical institutions and connected to major PACS systems nationwide. FxMammo will complement LPIXEL’s existing diagnostic suite by addressing a critical unmet need: early and accurate detection of breast cancer in women with dense breasts, which is particularly common across Asian populations. With regulatory approvals already secured in seven jurisdictions across Asia, this agreement marks a significant step forward in FathomX go-to-market strategy—demonstrating how regional collaboration can lower barriers to adoption for validated AI solutions in clinical practice. #AI #medicalimaging #breastcancer #medtech #femalehealth Masakazu KOYANAGI Stephen Lim Mengling 'Mornin' Feng Mikael Hartman https://lnkd.in/dzYKsdg2

I was honored to speak on the “Reimagining Healthcare Innovation” panel at the CHISEL Healthcare InnoMatch Networking Session 2025. It was great to return to CHI and share insights with fellow panelists, Glenn Neo Wendy Wu Linda Chow and Elizabeth Pan, from across the community and industry. As a CHISEL Healthcare InnoMatch 2022 awardee, FathomX is grateful for the support we received in driving the clinical adoption and evaluation of our AI solution for breast cancer detection. CHI’s collaborative environment—uniting public healthcare, startups, and technology enablers—has been instrumental in accelerating medtech solutions and adoption. We appreciate the opportunity to demonstrate how our AI solution can bring even greater value to healthcare. It’s always a pleasure to reconnect with the CHI community and stay inspired by the latest innovations shaping our field! #HealthcareInnovation #CHISEL #HealthTech #AIinHealthcare #InnoMatch #DigitalTransformation

We are pleased to collaborate with Global Health Services to improve access to AI-powered breast cancer screening in underserved communities across the UK. This partnership reflects our commitment to advancing early and accurate detection through clinically validated AI solutions, supporting healthcare providers in delivering better patient outcomes. Singapore’s health tech sector continues to drive innovation in medical AI, and we look forward to contributing to meaningful improvements in healthcare equity through this collaboration. We appreciate Global Health Services for their shared commitment to this important mission. #AI #digitalhealth #breatcancer #femalehealth

Stephen Lim, Co-Founder of FathomX, shares his experience on the MedTech Innovator Asia Pacific U.S. Market Access Program: “We could tap on and map what we already know in other countries–whether it is applicable in the U.S. or not, how they are and are not practical, and how things are done differently in the U.S.. Beyond that, they provided link-ups and direction to the right individuals and contacts to help us scale the next pathways.” With tailored guidance and unparalleled connections, this program equips MedTech startups with the knowledge and support to navigate and thrive in the U.S. market. 🚀 Apply now for the 2025 U.S. Market Access Program: https://lnkd.in/ghAJAvu7  #MedTech #USMAP #MTIAPAC #Innovation #HealthTech #DigitalHealth #Diagnostics #Singaporestartups #Startups

🌟FathomX co-founder, Prof. Mengling 'Mornin' Feng, participated this week as a distinguished speaker at the Hewlett Packard Enterprise Discover More AI Singapore 2024. Prof. Feng shared insights into how FathomX’s AI solution, FxMammo, is driving advancements in breast cancer screening, contributing to improved healthcare outcomes across the region. We thank Hewlett Packard Enterprise (HPE) for featuring FxMammo at this significant event and for their continued support of innovative startups like FathomX! This partnership underscores our shared commitment to leveraging technology to advance healthcare in Singapore and beyond.

🚀FathomX is honored to be featured in The Straits Times coverage of the National Health Innovation Centre (NHIC) 10th anniversary. Thank you to NHIC and Prof. Benjamin Ong for supporting FxMammo, our AI-enabled software improving mammogram accuracy and efficiency. Congratulations to NHIC on a decade of advancing healthcare innovation!🌟

🧡 Thank you National University of Singapore and Saw Swee Hock School Of Public Health for mentioning our work inventing the future and fighting breast cancer with AI: "According to the National Population Health Survey 2022, fewer than 40% of Singaporean women aged 50 to 69 have had a mammogram in the past two years, even though regular screenings are vital. One reason for this low uptake is the limitations of existing screening technology. In CNA’s Deep Tech: Inventing The Future series, the spotlight is shone on FxMammo, an AI-powered tool designed to analyse mammogram images by providing radiologists with a heat map and cancer probability score. Hear from Assoc Prof Mikael Hartman and Assist Prof Mengling 'Mornin' Feng as they share their experience in the development of FxMammo and discuss its potential to transform breast cancer detection."

According to the National Population Health Survey 2022, fewer than 40% of Singaporean women aged 50 to 69 have had a #mammogram in the past two years, even though regular screenings are vital. One reason for this low uptake is the limitations of existing screening technology.   In CNA's Deep Tech: Inventing The Future series, the spotlight is shone on FxMammo, an AI-powered tool designed to analyse mammogram images by providing radiologists with a heat map and cancer probability score.    Hear from Assoc Prof Mikael Hartman and Assist Prof Mengling 'Mornin' Feng as they share their experience in the development of FxMammo and discuss its potential to transform #breastcancer detection.   Learn more at https://lnkd.in/gGwPYBRW.    #NUS #NUSPublicHealth #publichealth #SSHSPH #health

🌟Our CEO Stephen Lim is speaking alongside regulators, policymakers and industry leaders at the Insights Forum™, held from 4 to 5 November 2024. Centred around Digital Assets, AI, Quantum, and Sustainability, the Insights Forum™ aims to unlock the wealth of opportunities offered in the adoption of technologies, digital infrastructure and new product developments. You can request an invite here: https://lnkd.in/eFbs-VUj. Hope to see you there! #InsightsForum @Elevandi